COMMUNIQUÉS West-GlobeNewswire

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
22/04/2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach [...]
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
22/04/2026
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
22/04/2026
Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. ( [...]
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
22/04/2026
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
22/04/2026
PARIS, France – 22 April 2026 : Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster [...]
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
22/04/2026
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported [...]
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
22/04/2026
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today [...]
Repligen to Report First Quarter 2026 Financial Results
22/04/2026
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first [...]
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
22/04/2026
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor Atopic dermatitis [...]
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
22/04/2026
SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today [...]
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
22/04/2026
NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that updated [...]
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
22/04/2026
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate with previously [...]
Axe Compute Secures $260 million, Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment
22/04/2026
Redefining enterprise AI infrastructure: enterprises no longer adapt to cloud constraints — they specify what they need, and Axe Compute delivers it PITTSBURGH, April 22, 2026 (GLOBE NEWSWIRE) -- Axe Compute Inc. ( [...]
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
22/04/2026
Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support initiation of [...]
Stereotaxis Announces First MAGiC Procedures in the United States
22/04/2026
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US [...]
Kestra Showcases Accelerated Innovation at HRS 2026
22/04/2026
KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it will exhibit at Heart Rhythm [...]
Glyco Harmony Drops Examined - 2026 Consumer-Focused Report on Ingredients, Claims & Label Insights
22/04/2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Glyco Harmony Drops has been gaining attention among people looking for natural ways to support blood sugar balance without relying solely on traditional approaches. As [...]
Medicines360 and Pharma Dynamics announce the launch of Avibela® in South Africa, Expanding Access to Long‑Acting Contraception and Treatment of Heavy Menstrual Bleeding
22/04/2026
SAN FRANCISCO and CAPE TOWN, South Africa, April 22, 2026 (GLOBE NEWSWIRE) -- Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine [...]
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
22/04/2026
AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE [...]

Pages